Symberix, an early-stage spin-out of the University of North Carolina at Chapel Hill, aims to improve human health by pioneering the development of symbiotic drugs that work by controlling bacteria without killing them. Symberix’s scientific founder, Matthew Redinbo, PhD, was the first to demonstrate the feasibility of therapeutically controlling the mammalian microbiome with small-molecule symbiotic drugs. Based on this breakthrough research, the company is advancing a first-in-class approach to improve the treatment of serious lower gastrointestinal (GI) diseases as well as mitigate the debilitating lower GI side effects associated with various cancer, pain, and immunosuppressive therapies. Symberix’s internal team and scientific/clinical/business advisors have a deep understanding of the microbiome as well as extensive drug discovery, clinical development and commercial biopharma experience. Our vision: Safe and effective pharmaceutical control of the microbiome.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 4819 Emperor Blvd.,
- in****@****rix.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- symberix.com
- Keywords
- Microbiome, Biotechnology, Drug Discovery.
- HQ
- Research Triangle Park, NC
Symberix Questions
Symberix's website is symberix.com
Symberix's LinkedIn profile is https://www.linkedin.com/company/symberix
Symberix has
3 employees.
View email and phone details for 3
employees at Symberix.
Symberix's industry is
Biotechnology Research
Symberix's top competitors are
Biogen,
Emc Leaders,
Femade Inc,
Tectaria Bio,
Resonantia Diagnostics,
Alcoa Consulting, Llc,
Tcrcure Biopharma Corp.,
Immunolight, Llc,
Karios Technologies, Inc.,
Lachancea Llc.
Symberix's support email address is info@symberix.com
Symberix's categories are Biotechnology Research
Symberix's founding year is 2013
